- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024…
HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its…
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+…
The MUHC Foundation backs the most innovative cancer researchers in the province. This year’s Le Bal Rouge gala supported the…
LEXINGTON, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company…
NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),…
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to…
• 24-week injection-free subgroup analyses from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in wet…
REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…
PARSIPPANY, NJ, June 04, 2024 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences® (OTCQX: IDXG), is proud to…